74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
N Nanosonics Ltd
N
Closed
SectorFinance
4.55 2.02
Overview
Share price change
24h
Min
4.55
Max
4.58
Income | 3M 9.8M |
|---|---|
Sales | 3.2M 94M |
P/E Sector Avg | 88.1 20.525 |
EPS | 0.011 |
Profit margin | 10.428 |
Employees | 466 |
EBITDA | -2.8M 9.8M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +8.77% upside |
Market Cap | 292M 1.3B |
|---|---|
Previous open | 2.53 |
Previous close | 4.55 |
Nanosonics Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Nanosonics Ltd Forecast
Price Target
By TipRanks
8.77% upside
12 Months Forecast
Average 4.927 AUD 8.77%
High 6 AUD
Low 4 AUD
Based on 8 Wall Street analysts offering 12 month price targets forNanosonics Ltd - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Nanosonics Ltd
Nanosonics Limited operates as an infection prevention company globally. The company manufactures and distributes the trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. Its product portfolio includes trophon2 that provides protection across various level disinfection HLD cycle; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
